PPHM Opinions 08/11/2014 22:37:08

New Post Public Reply Private Reply Replies (0) Message Board
Jake13
PPHM Opinions 08/11/2014 22:37:08 $PPHM
Quote:
Peregrine's made it this far, they might as well try to get it done alone. If we can squeak by in NSCLC then it opens Pandora's box.


That was a post from another respected poster in a PM weeks ago....


Looks like Pandoras box is starting to BULGE.....and I believe that squeak is going to be THUNDEROUS.

; )


wook
Yes well respected poster who's stance on PPHM is well documented, whose name I will not mention for wookies especially fear being accused of something so terrible that wookie will be gone.

That is a great comparison of PPHMs and a potential partners situation.....alas....as Billy Idol might say....OH OH....talking with myselElf oh oh, oh oh.......

It's shameful that a little control comes to this. Be careful.

I believe WE may have a dual partnership....bidding war or more brewing.
It's a big BIG World...let's hope Bavituximab and Peregrine have it covered.

imho

wook


w......Please announce no PPHM news again tomorrow!: )

Too funny.

Did we even hear that again from the "real" 8AM poster?????

Too bad so sad.

wook
Guess we will find out in approx 60 days if they applied and subsequently approved
Hey if they can fund one and partner the other that's fine with me. A little clarity on direction would be helpful to investors
Why not do both? But I agree, it's time we start getting some clear direction from management. Lock into a partnership or multiple partnerships and maybe we get better communication.

Where did the anti-PPHM crowd go? Ignore function doesn't block them all. You would think they would post something just to plead ignorance when the SEC boys come knocking.
good question on what this will do... or possibly do... to the Phase III lung.

I think that the DMC members live and die on statistics and probabilities and use "ALL" information at hand in any problem. Their current problem.... is sitting on the SunrRise Phase III trial of Peregrines and "if" new inputs are available to them to help them make their decision, then I'm certain they must use all available data.

IF during a clinical trial they find that all persons that pass on ... are all of a sudden found to have a "specific" DNA trait... then they may stop the trial because now the trial may be enrolling patients that are put at risk.

IF the DMC find new information regarding MDSC's or some other form of blood test that proves their immune system is performing optimally and they all happen to be on the Bavi arm of the trial.... ??

Well... I think they can stock the trial right at this point.

Peregrine just may see some intercept type (market cap) price spikes
Fingers crossed.
Wish I knew,

From my conversation last spring heard about biomarkers in liver and melanoma but was told that the lung trial was a straight one without them. Now that was last March and in this spinning world things seem to be changing quite rapidly.
What will this do to lung?
Quote:
now you need to think whether you move forward with that combo or advance the recent anti pd1 preclinical to phase I human trials


... with Pvalues of .004 that is 100% BTD from the FDA, which moves us right into Phase III

I'll agree with Sulaco... "Peregrine sitting in the cat bird seat.." is how I think he worded it
North.... I hope this means that my #1 hope of having CALICO involved with Peregrine is still alive ??

hmmm, maybe so after seeing that shade of green they used on their website.... looks awfully like that shade of green from Peregrines website lol : )

No, not serious about the green shade.... but after seeing green grass grow faster than Peregrines news cycle, one can get anxious

Big Pharma more anxious though and they don't like seeing all these combos coming out, especially with Pvalues of .004

My math friends who I told about Peregrine many months ago seen this today to call and say this is getting interesting now

Math is universal and they see a big, bright future in Tustin, CA

Big Pharma has hid behind Pvalues for many years... and now, its Pvalues that will unleash Peregrine as the top dog
We have phase II with taxane chemo in breast now you need to think whether you move forward with that combo or advance the recent anti pd1 preclinical to phase I human trials. Need better direction from leadership.
SW...you know THEY will try.....PG missed it.....DAD GUM!!!!

Send in PM.....

I'm all the place and really need to catch up on PPHMs' interesting news.

sheesh...where's my wookie copier...I need another one of me! LOL (NOT) 'sigh' yawn.....zzzzzzzzzz


wook
You know I was joking right dude?
Congrats brother porkchop!!!!! Bring the ship around.....I need a ride to the SS Thorpe......time to start prepping the ship.....Again......PPHM may be about to fuel her up with some serious hopium!!!!!

The trend will be our friend again.....just a month and half late. : ) imho


wook
Great PPHM can't even buy their own shares, how amusing lolz
That bodes well for your Kyoto projection IMO.
Here's some biomarkers from pr...

Quote:
Also, the once weekly combination treatment with ch1N11 and anti-PD-1 led to a 78% and 81% increase in intratumoral CD4+ and CD8+ T cells, two key indicators that show that tumor fighting immune cells are present in the local tumor environment, compared to the single agent anti-PD-1.


Local environment.

Got me another 1k today, early.

Imo.

porkchop11 :0
Scroll down for more posts ▼

Top 10 Most Recent News Articles

MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 8

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading

Top 5 Most Recently Viewed Articles

HeartCore's Journey: From Nasdaq Challenges to Growth Potential

Updated Category News Views 35

HeartCore's Nasdaq Delisting Challenge HeartCore Enterprises, Inc. (NASDAQ:HTCR), a provider of enterprise software and consulting services, is currently facing a significant challenge related to its listing on the Nasdaq Capital Market. The company has received notice of non-compliance with the minimum bid price requirement, which mandates that its stock price must be at...

Continue Reading
Mitchell Capital Expands Portfolio with Optelos Acquisition

Updated Category News Views 236

Mitchell Capital's New Acquisition of Optelos Mitchell Capital, a prominent private equity firm, recently announced a significant acquisition that marks a pivotal moment for their long-term investment strategy. They have secured a controlling interest in Optelos, a distinguished provider of digital twin platforms that are tailored for enhancing critical infrastructure...

Continue Reading
Tampa Bay Lightning and Scripps Sports Forge Exciting Partnership

Updated Category News Views 247

Partnership Announcement Between Tampa Bay Lightning and Scripps Sports The Tampa Bay Lightning have officially entered into an exciting multi-year partnership with Scripps Sports. This collaboration signifies a new chapter for the Tampa Bay Lightning, expanding their reach in broadcasting and enhancing viewer engagement with National Hockey League (NHL) games. Through...

Continue Reading
Kazia Therapeutics Sets Meeting with FDA on Glioblastoma Treatment

Updated Category News Views 61

Kazia Therapeutics Prepares for FDA Meeting on Paxalisib Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is set to meet with the U.S. Food and Drug Administration (FDA) to explore potential pathways for the registration of its innovative drug, Paxalisib, aimed at treating newly diagnosed glioblastoma multiforme (GBM). This crucial...

Continue Reading
Important Notice for Flux Power Investors on Lead Plaintiff Claims

Updated Category News Views 100

Overview of Flux Power Investor Claims Investors with concerns regarding their investments in Flux Power Holdings, Inc. (NASDAQ: FLUX) have much to consider as recent developments unfold. The national securities law firm, Faruqi & Faruqi, LLP, is actively investigating claims that could impact investor interests and is eager to assist those affected. Critical Investment...

Continue Reading